A new investment enables Curetis AG to continue developing its molecular diagnostic platform for the fast and reliable diagnosis of infectious diseases

CureVac GmbH today announced that the German regulatory authority, Paul-Ehrlich-Institute, has approved the Clinical Trial Application CTA to begin a Phase I clinical study with RNActive® - derived mRNA vaccine CV9103. The mRNA vaccine will be tested in patients with hormone-refractory metastatic prostate cancer.

For three days, from 9 to 11 October, more than 300 scientists from over 20 countries met at the Haus der Wirtschaft in Stuttgart to discuss the current state of research, the latest product developments and therapies for clinical application in regenerative medicine and stem cell research. For the third time, BioStar 2008, a Congress on Regenerative Biology and Medicine – on this occasion in cooperation with the 3rd Annual Congress of the German Society for Stem Cell Research – offered its international audience a unique platform for exchanging information on an interdisciplinary basis.

The press conference held by BioRegio STERN Management GmbH at the opening of the 3rd Congress on Regenerative Biology and Medicine ­
BioStar 2008 and the 3rd Congress of the German Society for Stem Cell Research on October 9 was dominated by the sensational research results
published only shortly beforehand by Prof. Thomas Skutella, Director of the Center for Regenerative Biology and Medicine (ZRM) at University Hospital
Tübingen, Germany.

A team of researchers headed by Thomas Skutella, director of the Center for Regenerative Biology and Medicine, has made a major breakthrough in stem cell research. This week, the scientists in Tübingen, with first author Sabine Conrad and in cooperation with colleagues from the University Department of Urology, director Prof. Arnulf Stenzl, present their study on isolating pluripotent human stem cells in the renowned science journal “Nature”, providing a true alternative to ethically controversial embryonic stem cells.

immatics biotechnologies GmbH is pleased to announce that it has won the second prize in the European Biotechnica Award 2008.